Episode 34 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 34, "Hope and the Huntington Disease Pipeline," features an interview with Daniel Claassen, MD, MS, director, Huntington’s Disease Clinic, and division chief, Behavioral and Cognitive Neurology, Vanderbilt University Medical Center. He discussed the recent news of trial program terminations from Roche and Wave Life Science,1,2 and the hope that remains in the Huntington disease pipeline despite these setbacks.
EPISODE BREAKDOWN
1:15 – Reaction to the Roche and Wave Life Sciences news
4:15 – Thoughts on tominersen prior to discontinuation
7:30 – Current state of SNP-targeting approaches
9:20 – The Huntington disease pipeline at this point
12:20 – The need to develop better outcome measures
14:50 – Ongoing work in nonpharmacologic approaches
13:00 – Takeaways and advice for neurologists
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
REFERENCES
1. Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials. News release. March 29, 2021. Accessed March 29, 2021. https://finance.yahoo.com/news/wave-life-sciences-provides-phase-200500861.html
2. Roche provides update on tominersen programme in manifest Huntington’s disease. News release. March 22, 2021. Accessed March 29, 2021. https://www.roche.com/media/releases/med-cor-2021-03-22b.htm
